ADT impacts mood of patients with prostate cancer, as perceived by partners
the ONA take:
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer and those negative effects are concurrently observed by their partners, according to a new study published online ahead of print in the journal Psycho-Oncology.
For the study, researchers from Mount Allison University in Sackville, Canada, and the University of British Columbia in Vancouver, Canada, sought to assess the relationship between androgen deprivation therapy and the mood of patients with prostate cancer and their partners.
Researchers enrolled 295 patients and 84 partners. Participants completed an online survey evaluating the patients' current mood and mood prior to therapy, relationship adjustment, and sexual function. Results were compared with that of men who received non-hormonal treatments. Results showed that 82 patients currently treated with androgen deprivation therapy reported worsened mood compared with the 213 not on hormonal therapy. Researchers found that the 42 partners of patients on hormonal therapy reported declines in the patient's mood, but to a greater extent that the patient.
"The psychological changes related to ADT can impact relationships and affect the quality of life of both PCa patients and partners," the authors conclude. "Patients and their partners are likely to benefit from being well informed about the psychological effects of androgen deprivation on men beginning ADT."
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|